TXMD
Income statement / Annual
Last year (2023), TherapeuticsMD, Inc.'s total revenue was $1.30 M,
a decrease of 98.14% from the previous year.
In 2023, TherapeuticsMD, Inc.'s net income was -$10.28 M.
See TherapeuticsMD, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.30 M
|
$69.96 M
|
$86.95 M
|
$64.87 M
|
$49.65 M
|
$16.10 M
|
$16.78 M
|
$19.36 M
|
$20.14 M
|
$15.03 M
|
| Cost of Revenue |
$0.00 |
$1.40 M |
$18.84 M |
$15.97 M |
$6.33 M |
$2.74 M |
$2.64 M |
$4.19 M |
$4.51 M |
$3.67 M |
| Gross Profit |
$1.30 M |
$68.57 M |
$68.11 M |
$48.90 M |
$43.31 M |
$13.36 M |
$14.14 M |
$15.17 M |
$15.64 M |
$11.35 M |
| Gross Profit Ratio |
1 |
0.98 |
0.78 |
0.75 |
0.87 |
0.83 |
0.84 |
0.78 |
0.78 |
0.76 |
| Research and Development
Expenses |
$0.00
|
$0.00
|
$7.09 M
|
$10.43 M
|
$19.79 M
|
$27.30 M
|
$33.85 M
|
$53.94 M
|
$72.04 M
|
$43.22 M
|
| General & Administrative
Expenses |
$0.00
|
$57.90 M
|
$92.60 M
|
$76.95 M
|
$58.82 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$108.20 M
|
$117.05 M
|
$114.23 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$8.90 M
|
$57.90 M
|
$200.80 M
|
$192.96 M
|
$174.11 M
|
$115.99 M
|
$57.70 M
|
$51.35 M
|
$28.72 M
|
$22.12 M
|
| Other Expenses |
$922,000.00 |
-$117,000.00 |
$272,000.00 |
$1.04 M |
$612,786.00 |
$2.28 M |
$695,631.00 |
$367,317.00 |
$95,719.00 |
$46,569.00 |
| Operating Expenses |
$9.83 M |
$57.90 M |
$207.88 M |
$204.44 M |
$194.52 M |
$143.58 M |
$91.77 M |
$105.42 M |
$100.83 M |
$65.40 M |
| Cost And Expenses |
$9.83 M |
$59.30 M |
$226.72 M |
$220.41 M |
$200.85 M |
$146.32 M |
$94.41 M |
$109.61 M |
$105.33 M |
$69.07 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$26.05 M |
$16.53 M |
$0.00 |
$7,699.00 |
$10,824.00 |
$17,442.00 |
$37,309.00 |
| Interest Expense |
$0.00 |
$0.00 |
$32.92 M |
$28.58 M |
$17.38 M |
$4.68 M |
$0.00 |
$0.00 |
$0.00 |
$260,027.00 |
| Depreciation &
Amortization |
$122,000.00
|
$1.19 M
|
$736,000.00
|
$5.47 M
|
$2.45 M
|
$293,886.00
|
$213,117.00
|
$132,451.00
|
$62,400.00
|
$52,467.00
|
| EBITDA |
-$8.40 M
|
$11.86 M
|
-$78.57 M
|
-$149.47 M
|
-$156.31 M
|
-$127.65 M
|
-$76.71 M
|
-$89.74 M
|
-$85.13 M
|
-$53.99 M
|
| EBITDA Ratio |
-6.45 |
0.3 |
-1.56 |
-2.33 |
-2.97 |
-7.93 |
-4.61 |
-4.64 |
-4.23 |
-3.59 |
| Operating Income Ratio
|
-6.55
|
0.29
|
-1.61
|
-2.4
|
-3.05
|
-8.09
|
-4.63
|
-4.66
|
-4.23
|
-3.6
|
| Total Other
Income/Expenses Net |
$781,000.00
|
-$117,000.00
|
$272,000.00
|
-$27.98 M
|
-$24.94 M
|
-$2.40 M
|
$703,330.00
|
$378,141.00
|
$113,161.00
|
-$176,149.00
|
| Income Before Tax |
-$7.74 M |
$1.07 M |
-$172.42 M |
-$183.52 M |
-$176.14 M |
-$132.62 M |
-$76.93 M |
-$89.88 M |
-$85.08 M |
-$54.22 M |
| Income Before Tax Ratio
|
-5.95
|
0.02
|
-1.98
|
-2.83
|
-3.55
|
-8.24
|
-4.58
|
-4.64
|
-4.22
|
-3.61
|
| Income Tax Expense |
$43,000.00 |
-$91.86 M |
$33.19 M |
$29.18 M |
$19.88 M |
$2.28 M |
-$7,699.00 |
$367,317.00 |
-$17,442.00 |
$306,596.00 |
| Net Income |
-$10.28 M |
$112.00 M |
-$205.60 M |
-$212.70 M |
-$196.03 M |
-$132.62 M |
-$76.93 M |
-$89.88 M |
-$85.08 M |
-$54.22 M |
| Net Income Ratio |
-7.89 |
1.6 |
-2.36 |
-3.28 |
-3.95 |
-8.24 |
-4.58 |
-4.64 |
-4.22 |
-3.61 |
| EPS |
-0.55 |
-10.35 |
-25.83 |
-38.58 |
-39.79 |
-29.47 |
-18.71 |
-22.92 |
-24.56 |
-18.11 |
| EPS Diluted |
-0.74 |
-10.35 |
-25.83 |
-38.58 |
-39.79 |
-29.47 |
-18.71 |
-22.92 |
-24.56 |
-18.11 |
| Weighted Average Shares
Out |
$13.89 M
|
$9.03 M
|
$7.96 M
|
$5.51 M
|
$4.93 M
|
$4.50 M
|
$4.11 M
|
$3.92 M
|
$3.46 M
|
$2.99 M
|
| Weighted Average Shares
Out Diluted |
$10.44 M
|
$9.03 M
|
$7.96 M
|
$5.51 M
|
$4.93 M
|
$4.50 M
|
$4.11 M
|
$3.92 M
|
$3.46 M
|
$2.99 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
